Gimenez Molina Y, Garcia Martinez V, Villanueva J, Davletov B, Gutierrez L. Multiple sclerosis drug FTY-720 toxicity is mediated by the heterotypic fusion of organelles in neuroendocrine cells. Sci Rep. 2019;9:18471 pubmed publisher

Baazim H, Schweiger M, Moschinger M, Xu H, Scherer T, Popa A, et al. CD8+ T cells induce cachexia during chronic viral infection. Nat Immunol. 2019;: pubmed publisher

Uchil P, Pi R, Haugh K, Ladinsky M, Ventura J, Barrett B, et al. A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus. Cell Host Microbe. 2019;25:87-100.e10 pubmed publisher

Panayotis N, Sheinin A, Dagan S, Tsoory M, Rother F, Vadhvani M, et al. Importin α5 Regulates Anxiety through MeCP2 and Sphingosine Kinase 1. Cell Rep. 2018;25:3169-3179.e7 pubmed publisher

Warkus E, Marikawa Y. Exposure-Based Validation of an In Vitro Gastrulation Model for Developmental Toxicity Assays. Toxicol Sci. 2017;157:235-245 pubmed publisher

Gao C, Qian Y, Huang J, Wang D, Su W, Wang P, et al. A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice. Mol Neurobiol. 2017;54:8348-8360 pubmed publisher

Yang D, Sun Y, Bhaumik S, Li Y, Baumann J, Lin X, et al. Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns. J Neurosci. 2014;34:16467-81 pubmed publisher

Tyler K. Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug. JAMA Neurol. 2015;72:10-3 pubmed publisher

Arvin A, Wolinsky J, Kappos L, Morris M, Reder A, Tornatore C, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72:31-9 pubmed publisher

Warnke C, Dehmel T, Ramanujam R, Holmén C, Nordin N, Wolfram K, et al. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology. 2014;83:2153-7 pubmed publisher

Rüger K, Ottenlinger F, Schroder M, Zivkovic A, Stark H, Pfeilschifter J, et al. Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells. Scand J Immunol. 2014;80:398-407 pubmed publisher

Wang M, Lu L, Liu Y, Gu G, Tao R. FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes. Exp Mol Pathol. 2014;97:218-24 pubmed publisher

Matheos D, Wood M. Unlocking the constraints on memory formation. Nat Neurosci. 2014;17:895-6 pubmed publisher

Höjer J, Olsson E. AV block II in a toddler after ingestion of a single tablet fingolimod. Clin Toxicol (Phila). 2014;52:644 pubmed publisher

Hait N, Wise L, Allegood J, O Brien M, Avni D, Reeves T, et al. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014;17:971-80 pubmed publisher

Ruvolo P, Ruvolo V, Jacamo R, Burks J, Zeng Z, Duvvuri S, et al. The protein phosphatase 2A regulatory subunit B55? is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta. 2014;1843:1969-77 pubmed publisher

You Y, Gupta V, Li J, Al Adawy N, Klistorner A, Graham S. FTY720 protects retinal ganglion cells in experimental glaucoma. Invest Ophthalmol Vis Sci. 2014;55:3060-6 pubmed publisher

Ntranos A, Hall O, Robinson D, Grishkan I, Schott J, Tosi D, et al. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway. J Neuroimmunol. 2014;270:13-21 pubmed publisher

Thangada S, Shapiro L, Silva C, Yamase H, Hla T, Ferrer F. Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction. J Urol. 2014;191:1508-16 pubmed publisher

Bunn P, Stanley A, de Labastida Rivera F, Mulherin A, Sheel M, Alexander C, et al. Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection. J Immunol. 2014;192:3709-18 pubmed publisher

Giovannoni G, Naismith R. Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes. Neurology. 2014;82:1196-7 pubmed publisher

Jokubaitis V, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82:1204-11 pubmed publisher

Miyazaki Y, Niino M, Fukazawa T, Takahashi E, Nonaka T, Amino I, et al. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Clin Immunol. 2014;151:127-35 pubmed publisher

Mohammad M, Tsai V, Ruitenberg M, Hassanpour M, Li H, Hart P, et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J Clin Invest. 2014;124:1228-41 pubmed publisher

Liu G, Bi Y, Wang R, Yang H, Zhang Y, Wang X, et al. Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells. J Immunol. 2014;192:3068-79 pubmed publisher

Cohen M, Maillart E, Tourbah A, de Sèze J, Vukusic S, Brassat D, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 2014;71:436-41 pubmed publisher

Rolf L, Muris A, Damoiseaux J, van Daele M, Hupperts R. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Neurology. 2014;82:1008-9 pubmed publisher

Sato D, Nakashima I, Bar Or A, Misu T, Suzuki C, Nishiyama S, et al. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol. 2014;268:95-8 pubmed publisher

Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen J, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674-80 pubmed publisher

Langer Gould A. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014;82:654-5 pubmed publisher

Wang L, Sammani S, Moreno Vinasco L, Letsiou E, Wang T, Camp S, et al. FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury. Crit Care Med. 2014;42:e189-99 pubmed publisher

Bigaud M, Guerini D, Billich A, Bassilana F, Brinkmann V. Second generation S1P pathway modulators: research strategies and clinical developments. Biochim Biophys Acta. 2014;1841:745-58 pubmed publisher

Tanaka M, Tanaka K. [New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 9. Therapeutic progress in multiple sclerosis and neuromyelitis optica]. Nihon Naika Gakkai Zasshi. 2013;102:1971-7 pubmed

Henault D, Galleguillos L, Moore C, Johnson T, Bar Or A, Antel J. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology. 2013;81:1768-72 pubmed publisher

Deshmukh V, Tardif V, Lyssiotis C, Green C, Kerman B, Kim H, et al. A regenerative approach to the treatment of multiple sclerosis. Nature. 2013;502:327-332 pubmed publisher

Zhang L, Wang H, Ji X, Cong Z, Zhu J, Zhou Y. FTY720 for cancer therapy (Review). Oncol Rep. 2013;30:2571-8 pubmed publisher

Pilz G, Harrer A, Wipfler P, Oppermann K, Sellner J, Fazekas F, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology. 2013;81:1654-8 pubmed publisher

Paul F, Bourdette D. Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences. Neurology. 2013;81:1648-9 pubmed publisher

Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138 pubmed publisher

Swain J, Mohapatra M, Borkar S, Aidhen I, Mishra A. Study of aqueous phase aggregation of FTY720 (fingolimod hydrochloride) and its effect on DMPC liposomes using fluorescent molecular probes. Phys Chem Chem Phys. 2013;15:17962-70 pubmed publisher

Kraft P, Göb E, Schuhmann M, Göbel K, Deppermann C, Thielmann I, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44:3202-10 pubmed publisher

Mackow E, Gorbunova E, Dalrymple N, Gavrilovskaya I. Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches. Lymphat Res Biol. 2013;11:128-35 pubmed publisher

Neviani P, Harb J, Oaks J, Santhanam R, Walker C, Ellis J, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013;123:4144-57 pubmed publisher

Ruuskanen J, Malm H, Airas L. [Multiple sclerosis and pregnancy]. Duodecim. 2013;129:1457-64 pubmed

Ruane D, Brane L, Reis B, Cheong C, Poles J, Do Y, et al. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J Exp Med. 2013;210:1871-88 pubmed publisher

Garland S. Are GPCRs still a source of new targets?. J Biomol Screen. 2013;18:947-66 pubmed publisher

Brunkhorst R, Kanaan N, Koch A, Ferreirós N, Mirceska A, Zeiner P, et al. FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS ONE. 2013;8:e70124 pubmed publisher

Oaks J, Santhanam R, Walker C, Roof S, Harb J, Ferenchak G, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013;122:1923-34 pubmed publisher

Natarajan V, Dudek S, Jacobson J, Moreno Vinasco L, Huang L, Abassi T, et al. Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury. Am J Respir Cell Mol Biol. 2013;49:6-17 pubmed publisher

Liu J, Zhang C, Tao W, Liu M. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci. 2013;123:163-9 pubmed publisher

Pitman M, Woodcock J, Lopez A, Pitson S. Molecular targets of FTY720 (fingolimod). Curr Mol Med. 2012;12:1207-19 pubmed

Hopkins C. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720). ACS Chem Neurosci. 2011;2:116-7 pubmed publisher

Kipp M, Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scler. 2012;18:258-63 pubmed publisher

Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011;12:213-28 pubmed

Strader C, Pearce C, Oberlies N. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod. 2011;74:900-7 pubmed publisher

Mehling M, Johnson T, Antel J, Kappos L, Bar Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76:S20-7 pubmed publisher

Lee C, Choi J, Chun J. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res. 2010;33:1567-74 pubmed publisher

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883-97 pubmed publisher

Potteck H, Nieuwenhuis B, Lüth A, van der Giet M, Kleuser B. Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation. Cell Physiol Biochem. 2010;26:67-78 pubmed publisher

Chun J, Hartung H. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91-101 pubmed publisher

Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173-82 pubmed publisher

Chiba K. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. Yakugaku Zasshi. 2009;129:655-65 pubmed

Chiba K. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. Nihon Rinsho Meneki Gakkai Kaishi. 2009;32:92-101 pubmed

Miron V, Schubart A, Antel J. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci. 2008;274:13-7 pubmed publisher

Kihara A, Igarashi Y. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta. 2008;1781:496-502 pubmed publisher

Mansoor M, Melendez A. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. Rev Recent Clin Trials. 2008;3:62-9 pubmed

Horga A, Montalban X. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother. 2008;8:699-714 pubmed publisher